Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$1.07 USD
-0.28 (-20.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.08 +0.01 (0.93%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Cardiol Therapeutics Inc. has a market cap of $111.61M, which represents its share price of $1.35 multiplied by its outstanding shares number of 82.68M. As a small-cap company, CRDL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CRDL 1.07 -0.28(-20.74%)
Will CRDL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?
Other News for CRDL
Roth bullish on Cardiol, says trial results enough to attract larger partner
Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements
Cardiol falls 14% to $1.16 after myocarditis study results
Cardiol ARCHER study not statistically significant, says Canaccord
Cardiol ARCHER study not statistically significant, says Canaccord